Brief: Yumanity Therapeutics Says YTX-7739 Demonstrates Pre-Clinical Proof Of Concept In Vivo Model
09/03/2021 13:37
March 9 (Reuters) - Yumanity Therapeutics Inc YMTX.O :
* YUMANITY THERAPEUTICS INC - YTX-7739 DEMONSTRATES
PHARMACOLOGICAL, PHYSIOLOGICAL, AND BEHAVIORAL PRE-CLINICAL
PROOF OF CONCEPT IN IN VIVO MODEL
Source text for Eikon: ID:nGNX4yKB3Q
Further company coverage: YMTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study